Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients

Pazopanib is an angiostatic tyrosine kinase inhibitor (TKI) presently used for cancer treatment, particularly in patients with renal cell carcinoma (RCC). This treatment can be accompanied by mild bleeding as an adverse effect. Given the role of protein tyrosine kinases in platelet activation proces...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Cardiovasc Med
Hlavní autoři: Tullemans, Bibian M. E., Nagy, Magdolna, Sabrkhany, Siamack, Griffioen, Arjan W., oude Egbrink, Mirjam G. A., Aarts, Maureen, Heemskerk, Johan W. M., Kuijpers, Marijke J. E.
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2018
Témata:
Cardiovascular Medicine
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6232667/
https://ncbi.nlm.nih.gov/pubmed/30460241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcvm.2018.00142
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky